Table 1.
Correlation of high and low expression of miR-196a with clinical, pathological, and serological features of patients with hepatocellular carcinoma.
| Variable | Total | miR-196a Expression | p Value | |
|---|---|---|---|---|
| (n = 83) | High (n = 42) | Low (n = 41) | ||
| Patient demographics | ||||
| Age 1 | 51 (44–63.5) | 47.5 (43–58.3) | 56 (45–64) | 0.0369 |
| Male, No (%) | 70 (84.3) | 35 (83.3) | 35 (85.4) | 1.0 |
| Cirrhosis, No (%) | 38 (45.8) | 20 (47.6) | 18 (43.9) | 0.9049 |
| Diabetes mellitus, No (%) | 10 (12.0) | 5 (11.9) | 5 (12.2) | 1.0 |
| Serum biochemistries 1 | ||||
| Albumin (g/dL) | 4.0 (3.6–4.1) | 3.9 (3.4–4.1) | 4.0 (3.8–4.3) | 0.0386 |
| ALT (IU/L) | 43 (34–56.8) | 44 (34–65) | 40 (34–55) | 0.4064 |
| AST (IU/L) | 39.5 (30–58.5) | 42 (31.5–60.3) | 37 (29.8–56.5) | 0.4132 |
| Total bilirubin (mg/dL) | 0.8 (0.6–1.0) | 0.8 (0.6–1.0) | 0.8 (0.6–1.0) | 0.8798 |
| ALP (IU/L) | 84 (62.5–107) | 84 (61–103) | 83 (65–107) | 0.8695 |
| Viral factors | ||||
| HBeAg (Positive/Negative) | 10/46 | 8/22 | 2/24 | 0.1338 |
| HBV genotype (B/C) | 49/27 | 25/14 | 24/13 | 1.0 |
| HBV DNA (copies/mL) 1 | 1.96 × 105 (1.41 × 104–1.81 × 106) |
2.02 × 105 (1.81 × 104–1.46 × 106) |
1.16 × 105 (1.09 × 104–2.06 × 106) |
0.9242 |
| Tumor factors | ||||
| Tumor size (cm) 1 | 4 (2.5–7.3) | 4.5 (2.5–8.3) | 3.5 (2.5–6.5) | 0.2981 |
| AFP (ng/mL), < 20 vs ≥ 20 | 37/44 | 12/28 | 25/16 | 0.0100 |
| Differentiation (Well/Moderate/Poor) | 2/67/14 | 1/33/8 | 1/34/6 | 0.8656 |
| HCC pattern (Solitary/Multiple) | 64/19 | 31/11 | 33/8 | 0.6435 |
| Microvascular invasion (Yes/No) | 32/51 | 19/23 | 13/28 | 0.298 |
| Macrovascular invasion (Yes/No) | 9/74 | 8/34 | 1/40 | 0.0375 |
| Tumor stage (I vs II + III + IV) | 42/41 | 16/26 | 26/15 | 0.0369 |
| Follow-up (months) 1 | 42 (26.5–51.5) | 40.5 (26.5–47.8) | 43 (27–53) | 0.3942 |
1 Data are presented with median and interquartile range. AFP: alpha-fetoprotein; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HBV: hepatitis B virus; HCC: hepatocellular carcinoma.